BMRN vs CARL · P/E 40, rev $1.76B vs rev $50.5M
Biomarin Pharmaceutical Inc (BMRN) versus Carlsmed, Inc. Common Stock (CARL) — a side-by-side from cached financials, not a winner call.
Biomarin Pharmaceutical Inc (BMRN) is a biotechnology company listed on NASDAQ.
Carlsmed, Inc. Common Stock (CARL) is a health information services company listed on NASDAQ.
Latest reported BMRN revenue for 2026-06-30 was $1.76B. Net income was $150.3M. BMRN currently screens at market cap $10.63B and trailing P/E 39.6.
Latest reported CARL revenue for 2025-12-31 was $50.5M. Net income was -$29.6M. Revenue was up 85.9% from 2024-12-31 to 2025-12-31. CARL currently screens at market cap $299.7M.
BMRN currently screens at market cap $10.63B and trailing P/E 39.6. CARL currently screens at market cap $299.7M.
Not investment advice. Open the BMRN and CARL stock pages for the full models.
Not investment advice.